Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review

P Molero, JA Ramos-Quiroga, R Martin-Santos… - CNS drugs, 2018 - Springer
Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce
a rapid-onset antidepressant effect in treatment-resistant depression. Ketamine causes …
被引用次数：255 相关文章 所有 7 个版本
[PDF] academia.edu

Esketamine: a glimmer of hope in treatment-resistant depression

U Kaur, BK Pathak, A Singh, SS Chakrabarti - European archives of …, 2021 - Springer
The motive of this article is to review the pharmacological and clinical aspects of esketamine
(ESK), an NMDA-receptor antagonist approved recently by the FDA for treatment-resistant …
被引用次数：60 相关文章 所有 7 个版本
[HTML] nih.gov

[HTML][HTML] Intranasal esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant

R Bahr, A Lopez, JA Rey - Pharmacy and Therapeutics, 2019 - ncbi.nlm.nih.gov
Major depressive disorder (MDD) affects more than 16 million adults each year in the United
States. 1 The incomplete response that many persons experience with current …
被引用次数：108 相关文章 所有 7 个版本
[PDF] cambridge.org

Esketamine for treatment resistant depression: a trick of smoke and mirrors?

C Gastaldon, D Papola, G Ostuzzi… - … and Psychiatric Sciences, 2020 - cambridge.org
In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray
formulation of esketamine for the treatment of resistant depression in adults. Esketamine is …
被引用次数：49 相关文章 所有 12 个版本

Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression

C Perez-Ruixo, S Rossenu, P Zannikos, P Nandy… - Clinical …, 2021 - Springer
Background Esketamine nasal spray is approved for treatment-resistant depression.
Objective The objective of this study was to characterize the pharmacokinetics of esketamine …
被引用次数：43 相关文章 所有 5 个版本